Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dexmedetomidine
Drug ID BADD_D00629
Description An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
Indications and Usage For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia
Marketing Status approved; vet_approved
ATC Code N05CM18
DrugBank ID DB00633
KEGG ID D00514
MeSH ID D020927
PubChem ID 5311068
TTD Drug ID D0U3DU
NDC Product Code 55150-209; 81092-1180; 16729-432; 68083-527; 81092-1120; 67457-251; 70860-605; 66794-230; 66794-238; 62068-308; 16729-239; 71288-505; 66794-233; 71872-7150
UNII 67VB76HONO
Synonyms Dexmedetomidine | MPV-1440 | MPV 1440 | MPV1440 | Precedex | Dexmedetomidine Hydrochloride | Hydrochloride, Dexmedetomidine
Chemical Information
Molecular Formula C13H16N2
CAS Registry Number 113775-47-6
SMILES CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tachycardia02.03.02.0070.000392%Not Available
Tachypnoea22.02.01.0140.000196%Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Torsade de pointes02.03.04.0050.000196%Not Available
Unresponsive to stimuli17.02.05.0310.000327%Not Available
Urinary retention20.02.02.0110.000131%
Urinary tract infection11.01.14.004; 20.08.02.001--
Ventricular arrhythmia02.03.04.006--
Ventricular fibrillation02.03.04.0080.000457%
Ventricular tachycardia02.03.04.0100.000196%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Withdrawal syndrome19.07.06.023; 08.06.02.0120.000327%Not Available
General physical health deterioration08.01.03.0180.000131%Not Available
Bradyarrhythmia02.03.02.0150.000261%Not Available
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Cardiopulmonary failure22.02.06.004; 02.05.01.0040.000131%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Haemodynamic instability24.03.02.0060.000392%Not Available
Respiratory tract congestion22.02.07.003--Not Available
Haemorrhage24.07.01.002--Not Available
Cerebrovascular insufficiency24.04.06.004; 17.08.02.0030.000131%Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Cardiac disorder02.11.01.003--Not Available
Infarction24.04.02.017--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages